Table 2.

Commonly used maintenance therapies for relapsing MOGAD

Therapy	Mechanism	Target regimen
Azathioprine	Interference with purine synthesis leading to reductions in B- and T-cell proliferation	2–3 mg/kg daily
Intravenous immunoglobulin	Modulation of lymphocyte function and antigen presentation; autoantibody neutralization	1000 mg/kg every 3–4 weeks
Mycophenolate mofetil	Inhibition of inosine monophosphate dehydrogenase leading to reductions in B- and T-cell proliferation	1000 mg twice daily
Prednisone	Broad spectrum immunosuppression	10 mg daily
Rituximab	CDC-mediated B-cell depletion via CD20	1000 mg q6 months